Avastin, Perjeta and Neumega
are among the drugs Dr.
Prior commercialization of Mylotarg, Neumega
and launch of Torisel for RCC will provide Wyeth with valuable insight into the oncology market 115
Avonex - Betaseron - Rebif - Copaxone - Novantrone - ABT 874 - Rituxan - Campath - Zenapax - MLN1202 - Remicade - Enbrel - Kineret - Orencia - Rituxan - Remicade - Enbrel - Humira - Orencia - Rituxan - CDP-870 - Actemra - AMG 714 - Eculizumab - IDEC-151 - AMG 719 - TAK 715 - Golimumab - Denosumab - Pegsunercept - SCIO 469 - BMS 561392 - Belimumab - Neumega
- Belatacept - VX 702 - Denileukin - Riquent - Rituxan - LymphoStat-B - ETI-201 - AMG 412 - AMG 623 - Abatacept - TACI-lg - Actemra - TRX-1 - TV-4710 - Prestara - CellCept - Linomide - Humira - Kremezin - Neumega
- Tetomilast - CDP-870 - Tysabri - Prograf - Leukine - Alicaforsen - MLN-02 - Rebif - RDP58
His studies in recombinant DNA helped him drive marketing initiatives for high-science brands such as Neumega
, Neurontin, Videx and Zerit.
As a result of their work, several first-in-class products advanced not only into clinical development but also through FDA approval, including BeneFix R (recombinant Factor IX) and Neumega
R (recombinant IL-11).
Schwertschlag served for 10 years as head of clinical immunology and clinical pharmacology, leading a variety of clinical programs and contributing to the successful registration of Neumega
(IL-11) for oncology indications and infectious disease agent Factor IX.
Ryan joined Genetics Institute, Cambridge, Massachusetts, in 1995 as Vice President of Clinical Development and guided clinical programs that led to the licensure of products including Benefix, Neumega
, and InductOs.
Before TAP, he spent ten years at Genetics Institute/Wyeth as head of clinical immunology and clinical pharmacology and was involved in the successful registration of Neumega
(IL-11) in oncology and Factor IX.
In two cases, Neumega
was used to correct therapy-induced thrombocytopenia, and in the other two cases it was started before antiviral therapy to prevent further decreases in platelet counts.
In that capacity he helped manage the launch of BeneFIX and Neumega
and played a key role in the integration of Genetics Institute into American Home Products Corporation.
Worldwide pharmaceutical sales increased 3% for the 1998 third quarter and 4% for the first nine months due primarily to higher sales of Premarin products, Effexor, Synvisc (introduced in the 1997 fourth quarter), Neumega
(introduced in the 1997 fourth quarter), Ziac, BeneFix and generic pharmaceuticals offset, in part, by the voluntary market withdrawal of the Company's antiobesity products in the 1997 third quarter and Duract in the 1998 second quarter, and lower sales of Oruvail and biologicals.
Gage stated, "Genetics Institute will submit its Biological License Application on Neumega
(IL-11), for stimulating the growth of platelets, before the end of the year and has recently received a unanimous recommendation for approval from a FDA medical advisory committee for BeneFix coagulation factor IX (recombinant), a blood clotting therapy used to treat Hemophilia B.